Nizatidine is new H2-receptor blocker with a thiazole ring. We evaluate the clinical efficacy and safety of the Nizatidine in 30 cases of endoscopically-proven peptic ulcer diseases. Nizatidine was administered 150 mg twice daily for 4 or 8 weeks and ...
Nizatidine is new H2-receptor blocker with a thiazole ring. We evaluate the clinical efficacy and safety of the Nizatidine in 30 cases of endoscopically-proven peptic ulcer diseases. Nizatidine was administered 150 mg twice daily for 4 or 8 weeks and then followed by endoscopy. Overall improvement of peptic ulcer diseases by endoscopic evaluation noted in 26 (86.9%) of 30 patients. 7 out of 8 cases (87.5%) of gastric ulcers and 19 out of 22 cases (86.3%) of duodenal ulcers had been healed in 4 or 8 weeks. Clinical symptoms of peptic ulcer diseases had been improved in 29 out of 30 cases (96.7%) after 4 or 8 weeks medication with Nizatidine. No significant clinical side effects and laboratory changes had been noticed during therapy. In conclusion, nizatidine was effective and safe drug for the treatment of peptic ulcer diseases.